ESC Premium Access

Cardiopulmonary exercise test based score for cardiovascular risk stratification in patients with heart failure and reduced ejection fraction

Congress Presentation

About the speaker

Doctor Pedro Freitas

Hospital de Santa Cruz, Carnaxide (Portugal)
2 presentations
0 follower

49 more presentations in this session

Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial

Speaker: Professor H. Duengen (Berlin, DE)

Thumbnail

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Speaker: Doctor T. Mondritzki (Wuppertal, DE)

Thumbnail

The use of Guideline recommended betablocker therapy in primary prevention ICD patients. Insight from Danish nationwide registries

Speaker: Doctor A. Huth Ruwald (Copenhagen, DK)

Thumbnail

The effect of angiotensin II type 2 receptor agonist treatment on doxorubicin induced heart failure

Speaker: Associate Professor N. Ermis (Malatya, TR)

Thumbnail

Triiodo-L-thyronine promotes the therapeutic efficacy for myocardial infarction of bone marrow mesenchymal stem cells

Speaker: Professor S. Nie (Beijing, CN)

Thumbnail

Access the full session

Poster session 7 - Heart failure / Left ventricular dysfunction

Speakers: Doctor P. Freitas, Professor H. Duengen, Doctor T. Mondritzki, Doctor A. Huth Ruwald, Associate Professor N. Ermis...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb